Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2023 | Upcoming advancements in subcutaneous levodopa therapy for PD

Carlo Colosimo, MD, FEAN, Santa Maria University Hospital, Terni, Italy, provides an exciting update on the advancements in optimizing levodopa therapy for Parkinson’s disease (PD) patients. One of the major developments is the upcoming registration in Europe of a new formulation for subcutaneous levodopa, which is particularly beneficial for individuals with advanced PD. This infusion therapy offers a less invasive alternative to traditional methods, with patients typically applying it in the morning and leaving it in place until the evening. Clinical trial results have shown significant improvements in motor fluctuations among those with advanced PD. This therapy is expected to become available across Europe in the coming year, offering new hope for PD patients. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.